Abbott’s new CardioMEMS HERO Heart Failure Reader wins FDA approval

USA—Abbott has received US Food and Drug Administration (FDA) approval for its CardioMEMS HERO device, marking a significant advancement in remote heart failure monitoring technology.

The next-generation pulmonary artery (PA) pressure reader equips patients and clinicians with daily data that helps detect heart failure progression before symptoms become apparent.

The device represents a major upgrade from previous models, boasting a compact design comparable to a laptop case.

Abbott engineered the HERO reader to be 60% lighter than its predecessor, making it practical for daily use and convenient enough for patients to carry during travel.

How the technology works

The HERO reader functions as part of Abbott’s broader CardioMEMS HF system, working alongside an implanted CardioMEMS PA sensor.

This sensor continuously monitors changes in PA pressure, which serves as a crucial indicator of deteriorating heart failure.

Patients simply lie on the device for less than 60 seconds to transmit a secure PA pressure reading directly to their healthcare team.

Healthcare providers use these daily readings to make informed decisions about medication adjustments or lifestyle modifications, enabling proactive management of heart failure progression.

This approach allows clinicians to intervene early, often preventing complications before patients experience noticeable symptoms.

Enhanced features for better patient experience

The updated design incorporates several improvements aimed at enhancing usability and reliability.

The device maintains consistent patient positioning during readings, ensuring accurate daily PA pressure trends that clinicians can trust for treatment decisions.

Built-in Wi-Fi and cellular capabilities give patients the flexibility to take readings from virtually any location with signal availability, eliminating geographical constraints on monitoring.

Abbott designed the HERO reader to remain compatible with all existing CardioMEMS PA sensors currently available on the market, ensuring seamless integration for current users.

Clinical impact and future outlook

Dr. Finn Gustafsson, chief medical officer and divisional vice-president of Abbott’s heart failure business, emphasized the device’s transformative potential.

He highlighted that the CardioMEMS HERO reader modernizes a proven remote patient management system while demonstrating a 57% reduction in heart failure hospitalizations.

Gustafsson explained that the new reader empowers patients to collaborate with their doctors in managing their condition outside traditional clinical settings.

This enhanced convenience improves both efficiency and the overall patient experience, making proactive heart failure management more accessible.

Expanding medical innovation

Beyond heart failure monitoring, Abbott continues advancing its medical technology portfolio.

The company recently launched a trial of its Volt pulsed-field ablation (PFA) system for atrial fibrillation treatment across 15 National Health Service (NHS) hospitals in the United Kingdom.

This system demonstrates the capability to perform ablation procedures with patients under conscious sedation rather than general anaesthesia, potentially improving patient comfort and procedural efficiency.